The United States Court of Appeals for the Federal Circuit has granted AstraZeneca’s request for a temporary injunction stopping Actavis from further sales of its budesonide inhalation suspension, according to Actavis. AstraZeneca has appealed the decision earlier this month that ruled US Patent No. 7,524,834 was invalid, after which Actavis announced the launch of its generic version of Pulmicort Respules.
According to Actavis, any budesonide suspension shipped prior to the temporary injunction is not affected by the order. The company also said that it is required to provide a response by February 20, 2015.
Read the Actavis press release.
